Venetoclax cas: 3257044-40-8

CAS NO: 1257044-40-8
Venetoclax cas: 3257044-40-8
Chemical Name: ABT-199
Molecular Formula: C45H50ClN7O7S
Formula Weight: 868.44
CAS No.: 1257044-40-8
Description Review
Description

Venetoclax is a small molecule inhibitor with high selectivity for B-cell lymphoma 2 (BCL-2) protein. It is used for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Venetoclax was approved by the US Food and Drug Administration (FDA) in 2016 and is marketed under the trade name Venclexta.

Chemical name:

(2S)-1-(9-(4-((3S)-2-methoxy-3-(6-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1(2H)-yl)-2-methylphenyl)-6-oxopyrimidin-5-yl)-N-(2-(2-morpholinoethoxy)ethyl)pyrrolidine-2-carboxamide

Molecular formula:

C45H50ClN7O7

Formula weight:

868.4 g/mol

CAS No:

3257044-40-8

Top 10 keywords from Google:

  1. Venetoclax mechanism of action
  2. Venetoclax dosing
  3. Venetoclax safety
  4. Venetoclax side effects
  5. Venclexta and rituximab
  6. Venetoclax resistance
  7. Venetoclax and acute myeloid leukemia
  8. Venetoclax and mantle cell lymphoma
  9. Venetoclax and multiple myeloma
  10. Venetoclax approval

Synonyms:

ABT-0199, ABT-199, RG7601, Venclexta

Health benefits:

Venetoclax has been shown to be highly effective in the treatment of CLL and SLL, which are two of the most common types of blood cancers. It works by inhibiting the BCL-2 protein, which is overexpressed in these cancers and helps the cancer cells survive. By inhibiting BCL-2, Venetoclax triggers apoptosis (cell death) in cancer cells, leading to tumor shrinkage and improved disease outcomes.

Potential effects:

Besides CLL and SLL, Venetoclax is being studied for the treatment of other types of blood cancers, including acute myeloid leukemia (AML), multiple myeloma, and mantle cell lymphoma. It is also being evaluated in combination with other drugs, such as rituximab, to improve its efficacy and reduce the risk of resistance.

Product mechanism:

Venetoclax works by inhibiting the BCL-2 protein, which is a key regulator of apoptosis. In normal cells, BCL-2 helps to prevent cell death, but in cancer cells, it is overexpressed and contributes to the survival of the tumor. Venetoclax binds to BCL-2 and prevents it from inhibiting apoptosis, triggering cell death in cancer cells. Venetoclax is highly selective for BCL-2 and does not affect other proteins in the BCL-2 family, which reduces the risk of side effects.

Safety:

Venetoclax has been shown to be generally safe and well-tolerated in clinical trials, with the most common side effects being diarrhea, nausea, and fatigue. However, there is a risk of serious side effects, including tumor lysis syndrome (TLS), which is a potentially life-threatening condition that can occur when large numbers of cancer cells are killed rapidly. TLS can cause kidney failure, cardiac arrhythmias, and other complications, so it is important to monitor patients closely and take steps to prevent it.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us